LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Suletud

1.27 -0.78

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.26

Max

1.32

Põhinäitajad
By Trading Economics
Sissetulek	17M -26M
Töötajad	171
EBITDA	19M -23M

Soovitused
By TipRanks
Soovitused	Müü
12 kuu keskmine prognoos	+56.25% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-27M 76M
Eelmine avamishind	2.05
Eelmine sulgemishind	1.27

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. veebr 2026, 22:04 UTC

Tulu

Coles 1st Half Net Profit Falls 11% on Worker Remediation Costs

26. veebr 2026, 23:55 UTC

Market Talk

Gold Edges Higher as Traders Digest U.S.-Iran Talks -- Market Talk

26. veebr 2026, 23:40 UTC

Omandamised, ülevõtmised, äriostud

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- Update

26. veebr 2026, 23:37 UTC

Market Talk

Japanese Stocks May Fall, Tracking Wall Street's Decline -- Market Talk

26. veebr 2026, 23:32 UTC

Tulu

Why Nvidia's Huge Numbers Don't Settle the Latest AI Fears -- Heard on the Street -- WSJ

26. veebr 2026, 23:19 UTC

Omandamised, ülevõtmised, äriostud

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26. veebr 2026, 23:18 UTC

Omandamised, ülevõtmised, äriostud

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26. veebr 2026, 23:12 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

26. veebr 2026, 23:12 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Netflix Gives Up in Bidding War Over Warner -- Market Talk

26. veebr 2026, 23:01 UTC

Omandamised, ülevõtmised, äriostud

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26. veebr 2026, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26. veebr 2026, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26. veebr 2026, 22:55 UTC

Omandamised, ülevõtmised, äriostud

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26. veebr 2026, 22:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

26. veebr 2026, 22:43 UTC

Market Talk

RBA Hike In March Is Being Underpriced -- Market Talk

26. veebr 2026, 22:33 UTC

Omandamised, ülevõtmised, äriostud

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26. veebr 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26. veebr 2026, 22:13 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Bidding War Over Warner Bros. Set to Continue -- Market Talk

26. veebr 2026, 21:59 UTC

Tulu

D-Wave Quantum Stock Rises on Earnings. Why a Revenue Miss Doesn't Seem to Matter. -- Barrons.com

26. veebr 2026, 21:58 UTC

Omandamised, ülevõtmised, äriostud

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26. veebr 2026, 21:49 UTC

Tulu

Coles 1H Net Profit Falls 11% on Worker Remediation Costs

26. veebr 2026, 21:45 UTC

Tulu

Coles Expects One-Off Costs of Around A$7 Million in 1H to Complete Simplification Process

26. veebr 2026, 21:44 UTC

Tulu

Coles Says Liquor Sales Fell 2.5% in First Seven Weeks of 3Q

26. veebr 2026, 21:44 UTC

Tulu

Coles Expects Market to Remain Highly Competitive

26. veebr 2026, 21:44 UTC

Tulu

Coles Says Supermarket Customers Remain Value Oriented

26. veebr 2026, 21:43 UTC

Tulu

Coles Says Supermarket Sales Revenue Up 5.3% in First Seven Weeks of 3Q When Tobacco Excluded

26. veebr 2026, 21:43 UTC

Tulu

Coles Says Supermarket Sales Revenue Up 3.7% in First Seven Weeks of 3Q

26. veebr 2026, 21:42 UTC

Omandamised, ülevõtmised, äriostud

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- WSJ

26. veebr 2026, 21:41 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Warner Bros. Earnings Report Falls Short. What It Means for the Netflix Takeover Saga. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

56.25% tõus

12 kuu keskmine prognoos

Keskmine 2 USD 56.25%

Kõrge 2 USD

Madal 2 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Müü

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.